Recent Posts
- AsclepiX Therapeutics Raises $10 Million to Advance Phase 1/2a Clinical Study of AXT107
- AsclepiX appoints Dr. Amir Shojaei as Chief Scientific Officer and Executive Vice President, Clinical Development
- AsclepiX Therapeutics, Inc. Appoints Robert J. Dempsey as Chief Executive Officer and President
- AsclepiX Therapeutics, Inc. Doses First Patient in Phase 1/2a Trial of AXT107 Intravitreal Self-Forming Gel Depot Peptide for Diabetic Macular Edema (DME)
- AsclepiX Therapeutics to Present at Solebury Trout Private Company Showcase on October 15, 2020
Recent Comments